Message #56 From:
NewsBot Date: February 28, 2007 04:00:00 AM
AEMD News Aethlon Medical Announces Lassa Virus Research Program
SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, announced today that it executed a research collaboration with The Southwest Foundation for Biomedical Research (SFBR) to study the Aethlon Hemopurifier® as a potential treatment for Lassa Fever. Lassa Fever is classified a category "A" bioterror threat in the United States, and is an endemic viral condition in Africa. Category "A" bioterror threats are defined by The Centers for Disease Control and Prevention (CDC) as agents that pose a risk to national security; are easily disseminated or transmitted from person to person; result in high mortality rates; could cause public panic and social disruption, and require special action for public health preparedness.
The studies will be performed at the nations only privately owned bio-safety level-4 (BSL-4) laboratory, located at the SFBR. BSL-4 facilities allow for the study of Lassa and other highly hazardous infectious agents requiring maximum containment. In addition to the SFBR collaboration, Aethlon initiated Hemopurifier® studies with researchers at both the CDC and The United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in January, and entered into a research partnership with the Government of India in December. Data obtained in these studies will be included in submissions with The Food and Drug Administration (FDA) and other government agencies.
About The Southwest Foundation for Biomedical Research
The Southwest Foundation for Biomedical Research (SFBR) is one of the world’s leading independent research organizations. It is home to the only privately owned bio-safety level-4 (BSL-4) laboratory in the United States. This maximum containment lab allows for research on lethal pathogens for which there are no treatments or vaccines, including bioterror and emerging pandemic threats. The SFBR, located on a 332-acre campus in San Antonio, Texas, partners with researchers around the world, targeting advances in heart disease, diabetes, obesity, cancer, hypertension, psychiatric disorders, premature newborn diseases, AIDS, hepatitis, malaria, and bioterror and emerging pandemic threats. Addition details can be accessed online at www.sfbr.org/pages/about_SFBR.php. Details specific to the SFBR BSL-4 research lab are available at www.sfbr.org/pages/about_resources2.php.
About Aethlon Medical
Aethlon Medical has developed a first-in-class medical device to treat infectious disease. The device, known as the Hemopurifier®, is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher, Frost & Sullivan, awarded Aethlon the 2006 Technology Innovation Award for its advances in the field of biodefense. The company has also initiated research on a second generation Hemopurifier® that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the HemopurifierTM technology can be found at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.Such potential risks and uncertainties include, without limitation, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.
